Chest
Original ResearchCOPDRelation Between COPD Severity and Global Cardiovascular Risk in US Adults
Section snippets
Study Sample
We used data from 6,266 individuals (projected to 66.8 million) aged ≥ 40 years who participated in the National Health and Nutrition Examination Survey III (1988-1994) in whom spirometry and CVE risk factor data were available and who did not have asthma (self-reported or physician diagnosed). The clinical and demographic data of these patients were then linked with National Death Index-linked mortality data through 2006. CVE mortality was defined by International Classification of Diseases,
Results
The prevalence of mild, moderate, and severe COPD was 12.1%, 8.7%, and 1.7%, respectively. Patients with vs without COPD had a higher mean age, systolic BP, history of smoking, and FRS, and those with severe COPD were more likely to have a family history of CVEs. They were also more likely to belong to intermediate and high global risk groups and to die of pulmonary events and CVEs. With increasing severity of COPD, FEV1, FEV1/FVC, and diastolic BP, the proportion of patients at low global risk
Discussion
The most important and novel finding in this study was that the addition of global CVE risk scores to lung function data significantly improved prognostic classification of individuals with COPD and, thus, should be used in risk stratification of patients with COPD. The findings also support previous observations that impaired lung function is a significant predictor of CVEs and mortality.19 However, by itself, measures of lung function have relatively poor resolution in predicting these events
Acknowledgments
Author contributions: Dr Lee had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Dr Lee: contributed to the study design, supervision of all project activities, and writing of the manuscript.
Ms J. Lee: contributed to the majority of analyses, interpretation of the results, and writing of the manuscript.
Ms K. Lee: contributed to additional analyses and editing of the manuscript.
Ms Luo: contributed to
References (27)
Scope of the COPD problem in North America: early studies of prevalence and NHANES III data: basis for early identification and intervention
Chest
(2000)- et al.
Effect of chronic obstructive pulmonary disease on survival of patients with coronary heart disease having percutaneous coronary intervention
Am J Cardiol
(2004) - et al.
Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients
Ann Epidemiol
(2006) - et al.
The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature
Chest
(2005) - et al.
Framingham risk score and prediction of lifetime risk for coronary heart disease
Am J Cardiol
(2004) - et al.
Elevated blood pressure among U.S. adults with diabetes, 1988-1994
Am J Prev Med
(2002) - et al.
Spirometric reference values for the 6-s FVC maneuver
Chest
(2003) COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity
Chest
(2002)- et al.
Reduction of morbidity and mortality by statin, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with COPD
Proc Am Coll Cardiol
(2006) - et al.
Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins
Chest
(2007)
Mortality in COPD: role of comorbidities
Eur Respir J
Life expectancy and years of life lost in chronic obstructive pulmonary disease: findings from the NHANES III Follow-up Study
Int J Chron Obstruct Pulmon Dis
Chronic obstructive pulmonary disease (COPD) fact sheet. World Health Organization website
Cited by (0)
Funding/Support: The authors have reported to CHEST that no funding was received for this study.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.